Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03457805 Recruiting - Prostate Cancer Clinical Trials

Prostatic Artery Embolization in Advanced Prostate Cancer

Start date: March 2, 2018
Phase: N/A
Study type: Interventional

This is a pilot study assessing efficacy and safety in patients with advanced prostate cancer.

NCT ID: NCT03440554 Recruiting - Prostate Cancer Clinical Trials

Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization

Start date: March 24, 2016
Phase: N/A
Study type: Interventional

This study aims to learn how to improve MRIs (Magnetic Resonance Imaging) that do not require the patient to be injected with a contrast dye. Researchers expect to learn how to better find and describe tumors in patients with prostate cancer. Participants have a whole body research MRI scan within 90 days of a standard-of-care imaging procedure. The research study will collect copies of those scans to compare to the research scans as part of the study analysis. Patients who have additional standard-of-care scans within 12 months after their research scan may be asked to have a second non-contrast MRI for research within 90 days of their follow-up standard of care imaging. The whole body MRI scan will be compared to the standard-of-care scan for prostate cancer detection and to assess patient response to standard-of-care treatment.

NCT ID: NCT03431753 Recruiting - Prostate Cancer Clinical Trials

Early and Accurate Detection of Prostate Cancer in General Practice

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Prostate cancer (PC) is the most common malignancy (4500 new cases/year) and the second leading cause of cancer-associated mortality (1200 deaths/year) among men in Denmark. PC is generally diagnosed on the basis of an elevated prostate specific antigen blood test followed by transrectal ultrasound (TRUS)-guided prostate biopsy. This study aims to test early detection of PC in general practice, using the STHLM3 model with superior specificity and sensitivity for clinically significant PC, combined with multiparametric magnetic resonance imaging (mpMRI) of the prostate and MR guided biopsy.

NCT ID: NCT03425240 Recruiting - Prostate Cancer Clinical Trials

Intra-operative Neuromodulation of the Pelvic Plexus

Start date: September 10, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the feasibility of electrical stimulation of nerves responsible for erectile function to evoke penile erection after surgery to remove the prostate (prostatectomy).

NCT ID: NCT03424850 Recruiting - Prostate Cancer Clinical Trials

Safety and Efficacy of 21 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Start date: February 27, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy.

NCT ID: NCT03424694 Recruiting - Prostate Cancer Clinical Trials

HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer

Start date: June 22, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate High-dose rate (HDR) brachytherapy (1 vs 2 fractions on single implant) as monotherapy for the treatment of low risk and intermediate risk prostate cancer

NCT ID: NCT03424213 Recruiting - Prostate Cancer Clinical Trials

Race-related Alternative Splicing: Novel Targets in Prostate Cancer

PCaP splicing
Start date: January 30, 2018
Phase: N/A
Study type: Observational

Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA men. Coded archival radical prostatectomy tissue specimens and annotated clinical data, questionnaire data, and ancestral genotyping data will be obtained from the racially diverse and federally funded North Carolina-Louisiana PCa Project (NC-LA PCaP). We will use 33 tissue specimens from each of the following 6 groups (n=198 total): white low aggressive, white intermediate aggressive, white high aggressive, AA low aggressive, AA intermediate aggressive and AA high aggressive. The aforementioned tissues will first be screened for tumor content and Gleason grade by a genitourinary pathologist. To identify race-related splice variants, RNA will be isolated for targeted sequencing of prioritized race-related alternatively spliced genes using the NimbleGen SeqCap Target Enrichment, SeqCap RNA System to capture regions of interest and the Illumina HiSeq sequencing platform to sequence these regions at a depth and coverage sufficient to accurately call alternative splicing events.

NCT ID: NCT03422679 Recruiting - Breast Cancer Clinical Trials

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Start date: December 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

NCT ID: NCT03419741 Recruiting - Breast Cancer Clinical Trials

Brain Stimulation For Cancer Smokers

Start date: October 21, 2017
Phase: N/A
Study type: Interventional

Smoking cessation and relapse prevention represent and important opportunity to improve cancer survival rates, reduce the risk of cancer treatment complication, and improve the quality of life of patients with and survivors of cancer. Previous studies showed that repetitive TMS (rTMS) reduced cue craving to smoking and treat nicotine dependent smokers. Recently one study completed by our team demonstrated that 10 sessions of rTMS over the left dorsolateral prefrontal cortex (DLPFC) reduced cigarette consumption and cue craving, and also increased quitting rate on target quit date in nicotine dependent smokers. Thus, we propose conducting a controlled, double-blind trial comparing the effect of treatments of active rTMS and sham rTMS on cigarette abstinence days, cigarette consumption and smoking craving during a 7-days of quit attempt period in 20 nicotine-dependent patients with cancer. Specific aims are: Aim 1: Assess a feasibility of the rTMS for smoking cessation in cancer patients. Aim 2: Obtain preliminary estimates of whether one-week active rTMS of left DLPFC tends to be more efficacious than sham rTMS during a 7-days of quit attempt laboratory model period increasing abstinence days, and also decreasing cigarette consumption and cue-elicited craving in cancer patients with smoking.

NCT ID: NCT03418324 Recruiting - Prostate Cancer Clinical Trials

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Start date: February 2018
Phase: Phase 2
Study type: Interventional

This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression without radiographic progression. A patient who is progressing on AR-therapy will continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue in parallel and independently.